We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $157.83 · 29 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Norges Bank Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Norges Bank Takes Position in Gilead Sciences, Inc. $GILD MarketBeat
Eurizon Capital SGR S.p.A. Invests $117.43 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Eurizon Capital SGR S.p.A. Invests $117.43 Million in Gilead Sciences, Inc. $GILD MarketBeat
Gilead Sciences (GILD) Valuation Check After Hepcludex Wins First FDA Approval For Hepatitis Delta - simplywall.st
Gilead Sciences (GILD) Valuation Check After Hepcludex Wins First FDA Approval For Hepatitis Delta simplywall.st
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-6.58 | — | — | $7.41B | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $1.04 | — | — | $6.67B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-1.04 | — | — | $21.19B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-2.05 | — | — | $13.64B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 20. | Maxim Group | — | Upgrade | Hold → Buy | — | Maxim Group: Hold → Buy |
| 2026. 05. 09. | Truist Securities | — | Maintain | Buy → Buy | — | Truist Securities: Buy |
| 2026. 05. 09. | RBC Capital | — | Maintain | Sector Perform → Sector Perform | — | RBC Capital: Sector Perform |
| 2026. 04. 14. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
| 2026. 04. 11. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
| 2026. 03. 10. | Jefferies | — | Initiate coverage | — → Buy | — | Jefferies: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 13,500 | $1.88B | 0.00% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 8,808 | $1.23B | 0.00% | — | New position |